Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1993 Sep;110(1):331–337. doi: 10.1111/j.1476-5381.1993.tb13813.x

Comparison of the cardiovascular and neural activity of endothelin-1, -2, -3 and respective proendothelins: effects of phosphoramidon and thiorphan.

G G Mattera 1, A Eglezos 1, A R Renzetti 1, J Mizrahi 1
PMCID: PMC2176041  PMID: 8106108

Abstract

1. In the anaesthetized, ganglion-blocked rat, intravenous boluses of endothelin-1, endothelin-2 and endothelin-3 induced a transient hypotensive effect followed by a potent long lasting pressor response (ED50 mmHg: 0.72 +/- 0.05, 1.8 +/- 0.2 and 2.7 +/- 0.3 nmol kg-1, respectively). The maximal effect for the three peptides was of a similar order of magnitude (delta MAP: 84 to 89 mmHg). Neither of these effects was influenced by phosphoramidon or thiorphan (10 mg kg-1, i.v.). 2. Intravenously administered big-endothelin-1 and -2 induced a transient (1-2 min) hypotension followed by a potent long lasting (> 25 min) vasopressor effect (ED50 mmHg: 1.8 +/- 0.2 and 6.7 +/- 0.4 nmol kg-1, respectively), with a similar maximal activity (delta MAP: 85 +/- 4 and 81 +/- 2.4 mmHg, respectively). The onset of the big-endothelin-1 vasopressor effect was more rapid (5-6 min) than that of big-endothelin-2 (10-13 min). Big-endothelin-3 was found to induce only a potent, long lasting (> 35 min) hypertension, with a maximal effect of 75 +/- 4.6 mmHg at 10 nmol kg-1 and an ED50 mmHg of 6.5 +/- 0.4 nmol kg-1. The onset of this effect was much slower (20-25 min) than that of the other proendothelins. Pressor responses induced by big-endothelin-1, -2 and -3 (3, 15 and 10 nmol kg-1, respectively) were markedly reduced (60, 80 and 100%) in the presence of phosphoramidon (10 mg kg-1, i.v.). Thiorphan (10 mg kg-1, i.v.) did not inhibit the effects of big-endothelin-1, -2 and -3.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
331

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990 Dec 20;348(6303):730–732. doi: 10.1038/348730a0. [DOI] [PubMed] [Google Scholar]
  2. D'Orléans-Juste P., Lidbury P. S., Telemaque S., Warner T. D., Vane J. R. Human big endothelin releases prostacyclin in vivo and in vitro through a phosphoramidon-sensitive conversion to endothelin-1. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S251–S255. doi: 10.1097/00005344-199100177-00072. [DOI] [PubMed] [Google Scholar]
  3. D'Orléans-Juste P., Télémaque S., Claing A. Different pharmacological profiles of big-endothelin-3 and big-endothelin-1 in vivo and in vitro. Br J Pharmacol. 1991 Oct;104(2):440–444. doi: 10.1111/j.1476-5381.1991.tb12448.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fagny C., Michel A., Léonard I., Berkenboom G., Fontaine J., Deschodt-Lanckman M. In vitro degradation of endothelin-1 by endopeptidase 24.11 (enkephalinase). Peptides. 1991 Jul-Aug;12(4):773–778. doi: 10.1016/0196-9781(91)90132-9. [DOI] [PubMed] [Google Scholar]
  5. Fukuroda T., Noguchi K., Tsuchida S., Nishikibe M., Ikemoto F., Okada K., Yano M. Inhibition of biological actions of big endothelin-1 by phosphoramidon. Biochem Biophys Res Commun. 1990 Oct 30;172(2):390–395. doi: 10.1016/0006-291x(90)90685-g. [DOI] [PubMed] [Google Scholar]
  6. Gardiner S. M., Kemp P. A., Bennett T. Inhibition by phosphoramidon of the regional haemodynamic effects of proendothelin-2 and -3 in conscious rats. Br J Pharmacol. 1992 Oct;107(2):584–590. doi: 10.1111/j.1476-5381.1992.tb12787.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gardiner S. M., Kemp P. A., Compton A. M., Bennett T. Coeliac haemodynamic effects of endothelin-1, endothelin-3, proendothelin-1 [1-38] and proendothelin-3 [1-41] in conscious rats. Br J Pharmacol. 1992 Jun;106(2):483–488. doi: 10.1111/j.1476-5381.1992.tb14360.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gomez-Sanchez C. E., Cozza E. N., Foecking M. F., Chiou S., Ferris M. W. Endothelin receptor subtypes and stimulation of aldosterone secretion. Hypertension. 1990 Jun;15(6 Pt 2):744–747. doi: 10.1161/01.hyp.15.6.744. [DOI] [PubMed] [Google Scholar]
  9. Hisaki K., Matsumura Y., Ikegawa R., Nishiguchi S., Hayashi K., Takaoka M., Morimoto S. Evidence for phosphoramidon-sensitive conversion of big endothelin-1 to endothelin-1 in isolated rat mesenteric artery. Biochem Biophys Res Commun. 1991 Jun 28;177(3):1127–1132. doi: 10.1016/0006-291x(91)90656-r. [DOI] [PubMed] [Google Scholar]
  10. Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T., Goto K., Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A. 1989 Apr;86(8):2863–2867. doi: 10.1073/pnas.86.8.2863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jaffer F. E., Knauss T. C., Poptic E., Abboud H. E. Endothelin stimulates PDGF secretion in cultured human mesangial cells. Kidney Int. 1990 Dec;38(6):1193–1198. doi: 10.1038/ki.1990.333. [DOI] [PubMed] [Google Scholar]
  12. Jones C. R., Hiley C. R., Pelton J. T., Mohr M. Autoradiographic visualization of the binding sites for [125I]endothelin in rat and human brain. Neurosci Lett. 1989 Feb 27;97(3):276–279. doi: 10.1016/0304-3940(89)90610-1. [DOI] [PubMed] [Google Scholar]
  13. Kashiwabara T., Inagaki Y., Ohta H., Iwamatsu A., Nomizu M., Morita A., Nishikori K. Putative precursors of endothelin have less vasoconstrictor activity in vitro but a potent pressor effect in vivo. FEBS Lett. 1989 Apr 10;247(1):73–76. doi: 10.1016/0014-5793(89)81243-8. [DOI] [PubMed] [Google Scholar]
  14. Kloog Y., Sokolovsky M. Similarities in mode and sites of action of sarafotoxins and endothelins. Trends Pharmacol Sci. 1989 Jun;10(6):212–214. doi: 10.1016/0165-6147(89)90261-7. [DOI] [PubMed] [Google Scholar]
  15. LaBella F. S., Queen G., Glavin G., Durant G., Stein D., Brandes L. J. H3 receptor antagonist, thioperamide, inhibits adrenal steroidogenesis and histamine binding to adrenocortical microsomes and binds to cytochrome P450. Br J Pharmacol. 1992 Sep;107(1):161–164. doi: 10.1111/j.1476-5381.1992.tb14480.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Le Monnier de Gouville A. C., Cavero I. Differential pharmacological profile of endothelin-1 and its precursor, big endothelin. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S362–S365. doi: 10.1097/00005344-199100177-00103. [DOI] [PubMed] [Google Scholar]
  17. Maggi C. A., Giuliani S., Patacchini R., Rovero P., Giachetti A., Meli A. The activity of peptides of the endothelin family in various mammalian smooth muscle preparations. Eur J Pharmacol. 1989 Dec 12;174(1):23–31. doi: 10.1016/0014-2999(89)90869-8. [DOI] [PubMed] [Google Scholar]
  18. Matsumura Y., Hisaki K., Takaoka M., Morimoto S. Phosphoramidon, a metalloproteinase inhibitor, suppresses the hypertensive effect of big endothelin-1. Eur J Pharmacol. 1990 Aug 21;185(1):103–106. doi: 10.1016/0014-2999(90)90216-s. [DOI] [PubMed] [Google Scholar]
  19. Matsumura Y., Ikegawa R., Takaoka M., Morimoto S. Conversion of porcine big endothelin to endothelin by an extract from the porcine aortic endothelial cells. Biochem Biophys Res Commun. 1990 Feb 28;167(1):203–210. doi: 10.1016/0006-291x(90)91751-d. [DOI] [PubMed] [Google Scholar]
  20. Matsumura Y., Ikegawa R., Tsukahara Y., Takaoka M., Morimoto S. N-ethylmaleimide differentiates endothelin converting activity by two types of metalloproteinases derived from vascular endothelial cells. Biochem Biophys Res Commun. 1991 Jul 31;178(2):531–538. doi: 10.1016/0006-291x(91)90140-3. [DOI] [PubMed] [Google Scholar]
  21. Matsumura Y., Tsukahara Y., Kuninobu K., Takaoka M., Morimoto S. Phosphoramidon-sensitive endothelin-converting enzyme in vascular endothelial cells converts big endothelin-1 and big endothelin-3 to their mature form. FEBS Lett. 1992 Jun 29;305(2):86–90. doi: 10.1016/0014-5793(92)80870-m. [DOI] [PubMed] [Google Scholar]
  22. McKay K. O., Black J. L., Armour C. L. Phosphoramidon potentiates the contractile response to endothelin-3, but not endothelin-1 in isolated airway tissue. Br J Pharmacol. 1992 Apr;105(4):929–932. doi: 10.1111/j.1476-5381.1992.tb09080.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. McMahon E. G., Palomo M. A., Moore W. M., McDonald J. F., Stern M. K. Phosphoramidon blocks the pressor activity of porcine big endothelin-1-(1-39) in vivo and conversion of big endothelin-1-(1-39) to endothelin-1-(1-21) in vitro. Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):703–707. doi: 10.1073/pnas.88.3.703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Miller W. L., Redfield M. M., Burnett J. C., Jr Integrated cardiac, renal, and endocrine actions of endothelin. J Clin Invest. 1989 Jan;83(1):317–320. doi: 10.1172/JCI113876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Okada K., Miyazaki Y., Takada J., Matsuyama K., Yamaki T., Yano M. Conversion of big endothelin-1 by membrane-bound metalloendopeptidase in cultured bovine endothelial cells. Biochem Biophys Res Commun. 1990 Sep 28;171(3):1192–1198. doi: 10.1016/0006-291x(90)90811-z. [DOI] [PubMed] [Google Scholar]
  26. Okada K., Takada J., Arai Y., Matsuyama K., Yano M. Importance of the C-terminal region of big endothelin-1 for specific conversion by phosphoramidon-sensitive endothelin converting enzyme. Biochem Biophys Res Commun. 1991 Oct 31;180(2):1019–1023. doi: 10.1016/s0006-291x(05)81167-2. [DOI] [PubMed] [Google Scholar]
  27. Pollock D. M., Opgenorth T. J. Evidence for metalloprotease involvement in the in vivo effects of big endothelin 1. Am J Physiol. 1991 Jul;261(1 Pt 2):R257–R263. doi: 10.1152/ajpregu.1991.261.1.R257. [DOI] [PubMed] [Google Scholar]
  28. Pons F., Touvay C., Lagente V., Mencia-Huerta J. M., Braquet P. Bronchopulmonary and pressor activities of endothelin-1 (ET-1), ET-2, ET-3, and big ET-1 in the guinea pig. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S326–S328. doi: 10.1097/00005344-199100177-00093. [DOI] [PubMed] [Google Scholar]
  29. Power R. F., Wharton J., Salas S. P., Kanse S., Ghatei M., Bloom S. R., Polak J. M. Autoradiographic localisation of endothelin binding sites in human and porcine coronary arteries. Eur J Pharmacol. 1989 Jan 24;160(1):199–200. doi: 10.1016/0014-2999(89)90675-4. [DOI] [PubMed] [Google Scholar]
  30. Randall M. D. Vascular activities of the endothelins. Pharmacol Ther. 1991;50(1):73–93. doi: 10.1016/0163-7258(91)90073-u. [DOI] [PubMed] [Google Scholar]
  31. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990 Dec 20;348(6303):732–735. doi: 10.1038/348732a0. [DOI] [PubMed] [Google Scholar]
  32. Takada J., Okada K., Ikenaga T., Matsuyama K., Yano M. Phosphoramidon-sensitive endothelin-converting enzyme in the cytosol of cultured bovine endothelial cells. Biochem Biophys Res Commun. 1991 Apr 30;176(2):860–865. doi: 10.1016/s0006-291x(05)80265-7. [DOI] [PubMed] [Google Scholar]
  33. Télémaque S., D'Orléans-Juste P. Presence of a phosphoramidon-sensitive endothelin-converting enzyme which converts big-endothelin-1, but not big-endothelin-3, in the rat vas deferens. Naunyn Schmiedebergs Arch Pharmacol. 1991 Oct;344(4):505–507. doi: 10.1007/BF00172593. [DOI] [PubMed] [Google Scholar]
  34. Vijayaraghavan J., Scicli A. G., Carretero O. A., Slaughter C., Moomaw C., Hersh L. B. The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase). J Biol Chem. 1990 Aug 25;265(24):14150–14155. [PubMed] [Google Scholar]
  35. Wiklund N. P., Ohlén A., Wiklund C. U., Hedqvist P., Gustafsson L. E. Endothelin modulation of neuroeffector transmission in rat and guinea pig vas deferens. Eur J Pharmacol. 1990 Aug 21;185(1):25–33. doi: 10.1016/0014-2999(90)90207-m. [DOI] [PubMed] [Google Scholar]
  36. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Mar 31;332(6163):411–415. doi: 10.1038/332411a0. [DOI] [PubMed] [Google Scholar]
  37. Yanagisawa M., Masaki T. Endothelin, a novel endothelium-derived peptide. Pharmacological activities, regulation and possible roles in cardiovascular control. Biochem Pharmacol. 1989 Jun 15;38(12):1877–1883. doi: 10.1016/0006-2952(89)90484-x. [DOI] [PubMed] [Google Scholar]
  38. Yano M., Okada K., Takada J., Hioki Y., Matsuyama K., Fukuroda T., Noguchi K., Nishikibe M., Ikemoto F. Endothelin-converting enzyme and its in vitro and in vivo inhibition. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S26–S28. doi: 10.1097/00005344-199100177-00008. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES